liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
The protective role of immunoglobulins in fungal infections and inflammation
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences.
Institute National Sante and Rech Med, France; University of Paris 06, France; University of Paris 05, France; France Indian Council Medical Research India, India.
Institute National Sante and Rech Med, France; University of Paris 06, France; University of Paris 05, France; France Indian Council Medical Research India, India.
2015 (English)In: Seminars in Immunopathology, ISSN 1863-2297, E-ISSN 1863-2300, Vol. 37, no 2, 187-197 p.Article, review/survey (Refereed) Published
Abstract [en]

Increased incidence of fungal infections in the immunocompromised individuals and fungi-mediated allergy and inflammatory conditions in immunocompetent individuals is a cause of concern. Consequently, there is a need for efficient therapeutic alternatives to treat fungal infections and inflammation. Several studies have demonstrated that antibodies or immunoglobulins have a role in restricting the fungal burden and their clearance. However, based on the data from monoclonal antibodies, it is now evident that the efficacy of antibodies in fungal infections is dependent on epitope specificity, abundance of protective antibodies, and their isotype. Antibodies confer protection against fungal infections by multiple mechanisms that include direct neutralization of fungi and their antigens, inhibition of growth of fungi, modification of gene expression, signaling and lipid metabolism, causing iron starvation, inhibition of polysaccharide release, and biofilm formation. Antibodies promote opsonization of fungi and their phagocytosis, complement activation, and antibody-dependent cell toxicity. Passive administration of specific protective monoclonal antibodies could also prove to be beneficial in drug resistance cases, to reduce the dosage and associated toxic symptoms of anti-fungal drugs. The longer half-life of the antibodies and flexibilities to modify their structure/forms are additional advantages. The clinical data obtained with two monoclonal antibodies should incite interests in translating pre-clinical success into the clinics. The anti-inflammatory and immunoregulatory role of antibodies in fungal inflammation could be exploited by intravenous immunoglobulin or IVIg.

Place, publisher, year, edition, pages
Springer Verlag (Germany) , 2015. Vol. 37, no 2, 187-197 p.
Keyword [en]
Fungi; Immunoglobulin; Inflammation; Aspergillus; Candida; Intravenous immunoglobulin; Therapy-Natural antibodies
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-115317DOI: 10.1007/s00281-014-0466-0ISI: 000349394700012PubMedID: 25404121OAI: diva2:795097

Funding Agencies|European Community [260338 ALLFUN, ANR-10-BLAN-1309 HYDROPHOBIN]; Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Universite Pierre et Marie Curie; Universite Paris Descartes

Available from: 2015-03-13 Created: 2015-03-13 Last updated: 2016-01-09

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Division of Clinical SciencesFaculty of Medicine and Health Sciences
In the same journal
Seminars in Immunopathology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 14 hits
ReferencesLink to record
Permanent link

Direct link